AVITA Medical Third Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update
Third Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update
Third Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update
Professor Fiona Wood, co-inventor of the RECELL System, described her experience treating more than 3,500 patients using RECELL and resulting benefits including reduced time to healing and decreased length of hospitalization The publication of the RECELL System pivotal trial in the treatment of second-degree burns was selected as a top journal publication for 2018 Link […]
Valencia, Calif., USA, and Melbourne, Australia, 13 March 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that management will present at the Cowen and Company 39th Annual Health Care Conference in Boston. The presentation is being made on 13 March 2019 from 11:20 a.m. to 11:50 a.m. EDT at […]
COSMOTEC has filed a JPMDA application for approval to market the RECELL System in Japan Valencia, Calif., USA, and Melbourne, Australia, 4 March 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that it has collaborated with COSMOTEC, an M3 Group company, to market and distribute the RECELL® Autologous Cell […]
–Sales temporarily interrupted while closing administrative and procedural open items related to EU certificates and unrelated to product performance -No impact on U.S. market Valencia, Calif., USA, and Melbourne, Australia, 4 March 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that sales of the RECELL® Device in the […]
Valencia, Calif., USA, and Melbourne, Australia, 28 February 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that it filed today with the ASX its Appendix 4D – Half-Year Report for the six months ended 31 December 2018. Revenues for First Six Months and Update on U.S. National Market Launch […]
Recent Highlights • Pre-launch U.S. product sales of A$1.1 million in second quarter • Successful preparation for U.S. national market launch in January 2019 • 26 abstracts highlighting RECELL® System clinical and economic benefits accepted for presentation at multiple burn conferences, including the American Burn Association (ABA) 51st Annual Meeting • A$41.7 million equity financing […]
RECELL System clinical benefits and cost savings featured in 26 presentations at four burn conferences in early 2019 Valencia, Calif., USA, and Melbourne, Australia, 29 January 2019 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicine company,today announced that 26 abstracts highlighting theclinical and cost savings benefits of the RECELL® Autologous Cell Harvesting Device […]
Shareholders approve 2nd Tranche of December 2018 equity placement Valencia, Calif., USA, and Melbourne, Australia, 14 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, in accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, announce the results of the votes and the proxies received in […]
Strong market response to the RECELL System approval in advance of U.S. launch with 36 burn centers actively reviewing the product or placing commercial orders Valencia, Calif., USA, and Melbourne, Australia, 8 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has commenced the U.S. national […]